MedTrace Logo

Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis

NCT04283747 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2020-07-10

No results posted yet for this study

Summary

B cells are considered major contributors to multiple sclerosis (MS) pathogenesis, a role that has taken on renewed importance with the advent of B-cell-depleting therapies. Rituximab is being increasingly utilized as an off-label treatment option across MS patients .

In addition, there have been increasing reports of rituximab causing hypogammaglobulinaemia and antibody deficiency across a variety of conditions including MS and related neuroinflammatory disorders.

Therefore, the purpose of this study is to evaluate the rate of hypogammaglobulinemia in rituximab-treated MS adult patients and to assess the correlation with vaccination response during the treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

Serum immunoglobulin titer

Serum IgG and IgM levels, VZV titer every 6 month at before rituximab administration 3 times

Sponsors & Collaborators

  • Mazandaran University of Medical Sciences

    lead OTHER

Principal Investigators

  • monireh ghazaeian · mazandaran university of medical science

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2022-10-31
Completion
2022-12-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04283747 on ClinicalTrials.gov